P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000846204.59341.a5 |
| _version_ | 1797287203275014144 |
|---|---|
| author | A. Röth M. Egyed S. Ichikawa Y. Ito J. S. Kim Z. Nagy N. Obara J. Panse H. Schrezenmeier S. Sica J. Soret K. Usuki S.-S. Yoon K. Benkali M. Buri P. Lundberg H. Patel K. Shinomiya S. Sreckovic J.-I. Nishimura |
| author_facet | A. Röth M. Egyed S. Ichikawa Y. Ito J. S. Kim Z. Nagy N. Obara J. Panse H. Schrezenmeier S. Sica J. Soret K. Usuki S.-S. Yoon K. Benkali M. Buri P. Lundberg H. Patel K. Shinomiya S. Sreckovic J.-I. Nishimura |
| author_sort | A. Röth |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:33Z |
| format | Article |
| id | doaj.art-fbc0fe0e7835460e8fc2e718026f85ce |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:33Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-fbc0fe0e7835460e8fc2e718026f85ce2024-03-02T06:40:51ZengWileyHemaSphere2572-92412022-06-01672472510.1097/01.HS9.0000846204.59341.a5202206003-00724P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSIONA. Röth0M. Egyed1S. Ichikawa2Y. Ito3J. S. Kim4Z. Nagy5N. Obara6J. Panse7H. Schrezenmeier8S. Sica9J. Soret10K. Usuki11S.-S. Yoon12K. Benkali13M. Buri14P. Lundberg15H. Patel16K. Shinomiya17S. Sreckovic18J.-I. Nishimura191 Department of Hematology and Stem Cell Transplantation, West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany2 Kaposi Mor Oktato Korhaz, Kaposvar, Hungary3 Tohoku University Hospital, Miyagi4 First Department of Internal Medicine, Hematology Division, Tokyo Medical University, Tokyo, Japan5 Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea6 Semmelweis University, Budapest, Hungary7 Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan8 University Hospital RWTH Aachen, Aachen9 Institute of Transfusion Medicine, University Hospital Ulm, Ulm, Germany10 Fondazione Policlinico Universitario A. Gemelli-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy11 Centre d’Investigation Clinique, Hôpital Saint-Louis, Paris, France12 NTT Medical Center Tokyo, Tokyo, Japan13 Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea14 Certara, Inc., Paris, France15 F. Hoffmann-La Roche, Ltd., Basel, Switzerland15 F. Hoffmann-La Roche, Ltd., Basel, Switzerland16 Genentech, Inc., South San Francisco, CA, United States of America17 Chugai Pharmaceutical Co., Tokyo15 F. Hoffmann-La Roche, Ltd., Basel, Switzerland18 Graduate School of Medicine, Osaka University, Osaka, Japanhttp://journals.lww.com/10.1097/01.HS9.0000846204.59341.a5 |
| spellingShingle | A. Röth M. Egyed S. Ichikawa Y. Ito J. S. Kim Z. Nagy N. Obara J. Panse H. Schrezenmeier S. Sica J. Soret K. Usuki S.-S. Yoon K. Benkali M. Buri P. Lundberg H. Patel K. Shinomiya S. Sreckovic J.-I. Nishimura P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION HemaSphere |
| title | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_full | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_fullStr | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_full_unstemmed | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_short | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_sort | p830 crovalimab maintains clinical benefit over long term treatment in patients with paroxysmal nocturnal hemoglobinuria results from the composer trial open label extension |
| url | http://journals.lww.com/10.1097/01.HS9.0000846204.59341.a5 |
| work_keys_str_mv | AT aroth p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT megyed p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT sichikawa p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT yito p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT jskim p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT znagy p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT nobara p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT jpanse p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT hschrezenmeier p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT ssica p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT jsoret p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT kusuki p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT ssyoon p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT kbenkali p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT mburi p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT plundberg p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT hpatel p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT kshinomiya p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT ssreckovic p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT jinishimura p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension |